Showing 3551-3560 of 6035 results for "".
- CooperCompanies Announces Executive Management Changeshttps://modernod.com/news/coopercompanies-announces-executive-management-changes/2480477/CooperCompanies announced two senior leadership changes that will enable the company to maximize current and future opportunities. Effective February 1, 2022, Dan McBride, Executive Vice President (EVP), Chief Operating Off
- Inspecs Acquires Hardy Amies Brandhttps://modernod.com/news/inspecs-acquires-hardy-amies-brand/2480476/Inspecs, a designer, manufacturer and distributor of eyewear frames and lenses, has announced the acquisition of the Hardy Amies brand, including all global intellectual property rights. Terms of the deal were not disclosed. Hardy Amies was founded by Sir Hardy Amie
- IOLCon Designed to Map Out the Road for Reliable IOL Calculationhttps://modernod.com/news/iolcon-is-mapping-out-the-road-for-reliable-iol-calculation/2480474/Internet database IOLCon announced updates to its website,
- Zeiss Celebrates 175 Years in Opticshttps://modernod.com/news/zeiss-celebrates-175-years-in-optics/2480468/This year, Zeiss celebrates its 175th year in business. Since the early days when Carl Zeiss created his first microscope, Zeiss has played a leading role in advancing the field of optics. From pioneering surgical microscopes and slit lamps, to developing optical glass and precision eye
- Santen to Introduce First Plant-Derived Eye Drop Bottle in EMEA to Help Reduce Reliance on Fossil Fuel-Based Plastichttps://modernod.com/news/santen-to-introduce-first-plant-derived-eye-drop-bottle-in-emea-to-help-reduce-reliance-on-fossil-fuel-based-plastic/2480457/Santen unveiled plans to launch t
- Opus Genetics Announces Agreement with Massachusetts Eye and Ear and Harvard Medical School to License Third Program for Inherited Retinal Diseasehttps://modernod.com/news/opus-genetics-announces-agreement-with-massachusetts-eye-and-ear-and-harvard-medical-school-to-license-third-program-for-inherited-retinal-disease/2480431/Opus Genetics, a gene therapy company developing treatments for orphan inherited retinal diseases, announced an agreement to license its third preclinical program to address mutations in the NMNAT1 gene, which cause a specific form of Leber congenital amaurosis (LCA), from Massa
- Johnson & Johnson Vision to Present New Data at AAO Demonstrating Benefits That New Innovations in Cataract Surgery Will Provide to Physicians and Patientshttps://modernod.com/news/johnson-johnson-vision-to-present-new-data-at-aao-demonstrating-benefits-that-new-innovations-in-cataract-surgery-will-provide-to-physicians-and-patients/2480412/Johnson & Johnson Vision will present a range of company-sponsored studies supporting new innovations in its cataract
- Johnson & Johnson Vision Presents Findings from New Myopia Research and Highlights Latest Contact Lens Innovations for Patients with Presbyopia at Academy 2021https://modernod.com/news/johnson-johnson-vision-presents-findings-from-new-myopia-research-and-highlights-latest-contact-lens-innovations-for-patients-with-presbyopia-at-academy-2021/2480391/Johnson & Johnson Vision announced that new myopia data outcomes will be presented at the upcoming 2021 American Academy of Optometry (AAO) annual
- AI-Powered Glaucoma Screening Test Delivers Rapid Resultshttps://modernod.com/news/ai-powered-glaucoma-screening-test-delivers-rapid-results/2480378/
- Opus Genetics Announces Two Leadership Appointmentshttps://modernod.com/news/opus-genetics-announces-two-leadership-appointments/2480367/Opus Genetics announced two key appointments to its founding executive team. Ash Jayagopal, PhD, has joined the company as Chief Scientific Officer (CSO); and Joe Schachle has joined as Chief Operating Officer (COO). “We were thrilled to launch Opus last month to advance an A